Arbutus Biopharma (ABUS) vs Olema Oncology (OLMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arbutus Biopharma (ABUS) has outperformed Olema Oncology (OLMA) over the past year, losing 6.7% versus a loss of 69.7%. Over five years, ABUS leads with a +28.4% price change compared with -66.4% for OLMA. Arbutus Biopharma is the larger company by market cap ($616.2 million vs $615.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | OLMA |
|---|---|---|
| Share price | $4.02 | $7.02 |
| Market cap | $616.24M | $615.00M |
| 1-day change | -1.23% | -1.82% |
| YTD return | -16.42% | -71.92% |
| 1-year return | -6.73% | -69.70% |
| 5-year return | +28.43% | -66.36% |
| P/E ratio (TTM) | 3.59 | — |
| EPS (TTM) | $1.12 | $-2.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | — |
| Revenue growth (YoY) | +128.21% | — |
| Net income (latest FY) | $-33.50M | $-162.45M |
| Operating margin | -270.96% | — |
| Net margin | -237.88% | — |
| 52-week high | $5.45 | $36.26 |
| 52-week low | $3.50 | $6.24 |
| Distance from 52-week high | -26.24% | -80.64% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +32.34% | +405.70% |
| Average volume | 4.98M | 1.27M |
| Shares outstanding | 153.29M | 87.61M |
| Employees | 19 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABUS has outperformed OLMA by 63.0 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Olema Oncology
OLMA stock →Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
ABUS vs OLMA FAQ
Which is bigger, Arbutus Biopharma or Olema Oncology?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $616.24M compared with $615.00M for Olema Oncology (OLMA).
Which stock has performed better over the past year, ABUS or OLMA?
ABUS returned -6.73% over the past 12 months, compared with -69.70% for OLMA (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Olema Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.